SCHEMBL4668056

SCHEMBL4668056

Cc1ccc(Cc2cc3c(cc2C=O)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 9/20 0.52
GNRHR P30968 4/20 0.45
HNF4A P41235 1/20 0.43
RXRB P28702 2/20 0.43
RXRG P48443 2/20 0.43
CYP26A1 O43174 2/20 0.41
CYP26B1 Q9NR63 2/20 0.41
SRC P12931 1/20 0.38
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947942 0.79 RXRA (0.44) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL4668297 0.78 RARB (0.66) RXRAHNF4ARXRBRXRGCYP26A1
SCHEMBL7071780 0.78 RXRA (0.52) RXRAGNRHRHNF4ARXRBRXRG
SCHEMBL7071777 0.78 RXRA (0.52) RXRAGNRHRHNF4ARXRBRXRG
SCHEMBL4668291 0.78 RARB (0.66) RXRAHNF4ARXRBRXRGCYP26A1
SCHEMBL4666519 0.75 RARA (0.50) RXRAGNRHRHNF4ARXRBRXRG
SCHEMBL4666520 0.75 RARA (0.50) RXRAGNRHRHNF4ARXRBRXRG
SCHEMBL9054943 0.75 RXRA (0.48) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL4669393 0.75 RXRA (0.50) RXRARXRBRXRGCYP26A1CYP26B1
SCHEMBL4666501 0.75 RXRA (0.37) RXRAGNRHRRXRBRXRGCYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324970-B1 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA HOFFMANN LA ROCHE (CH) 2008-11-05 EP disclosed
EP-1935869-A1 Retinoids for the treatment of emphysema F. HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
US-6777418-B2 FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-08-17 US disclosed
EP-1324970-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 EP disclosed
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders SYNTEX (U.S.A.) LLC 2002-06-27 US disclosed
WO-2002028810-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders RXRA, RXRG, RXRB RXRA 1/4885GNRHR 3224/4885HNF4A 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.